This company just had the best new drug launch of all-time

CNBC: Talking Numbers
Gilead Sciences announced better-than-expected earnings Wednesday, pushing shares higher. The results were driven by the launch of its new hepatitis C drug Sovaldi, which brought in $2.3 billion. So is it time to prescribe Gilead to your portfolio?
View Comments (0)